| A novel epigenetic signature for early diagnosis in lung cancer A Diaz-Lagares, J Mendez-Gonzalez, D Hervas, M Saigi, MJ Pajares, ... Clinical Cancer Research 22 (13), 3361-3371, 2016 | 136 | 2016 |
| Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity NR Mahadevan, EH Knelson, JO Wolff, A Vajdi, M Saigí, M Campisi, ... Cancer discovery 11 (8), 1952-1969, 2021 | 93 | 2021 |
| MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer M Saigi, JJ Alburquerque-Bejar, A Mc Leer-Florin, C Pereira, E Pros, ... Clinical Cancer Research 24 (18), 4579-4587, 2018 | 84 | 2018 |
| Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors E Pros, M Saigi, D Alameda, G Gomez-Mariano, B Martinez-Delgado, ... Annals of Oncology 31 (2), 274-282, 2020 | 35 | 2020 |
| Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy M Bergamino, AJ Rullan, M Saigí, I Peiró, E Montanya, R Palmero, ... BMC cancer 19, 1-9, 2019 | 32 | 2019 |
| Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front M Saigi, JJ Alburquerque-Bejar, M Sanchez-Cespedes Oncogene 38 (31), 5921-5932, 2019 | 30 | 2019 |
| SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade OA Romero, A Vilarrubi, JJ Alburquerque-Bejar, A Gomez, A Andrades, ... Nature communications 12 (1), 4319, 2021 | 28 | 2021 |
| Targeting KRAS in lung cancer beyond KRAS G12C inhibitors: The immune regulatory role of KRAS and novel therapeutic strategies M Cucurull, L Notario, M Sanchez-Cespedes, C Hierro, A Estival, ... Frontiers in Oncology 11, 793121, 2022 | 19 | 2022 |
| Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer M Saigi, A McLeer-Florin, E Pros, E Nadal, E Brambilla, ... Clinical and Translational Oncology 20, 881-888, 2018 | 18 | 2018 |
| Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma E Aliagas, A Alay, M Martínez-Iniesta, M Hernández-Madrigal, D Cordero, ... British Journal of Cancer 125 (10), 1365-1376, 2021 | 12 | 2021 |
| MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer R Yoshida, M Saigi, T Tani, BF Springer, H Shibata, S Kitajima, ... Cancer research 82 (21), 4079-4092, 2022 | 11 | 2022 |
| Small-cell lung cancer long-term survivor patients: how to find a needle in a haystack? A Plaja, T Moran, E Carcereny, M Saigi, A Hernández, M Cucurull, ... International Journal of Molecular Sciences 22 (24), 13508, 2021 | 11 | 2021 |
| Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data L Gutiérrez, A Royuela, E Carcereny, R López-Castro, ... BMC cancer 21 (1), 977, 2021 | 11 | 2021 |
| Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver M Domènech, AMM Marmol, JL Mate, A Estival, T Moran, M Cucurull, ... Oncotarget 12 (18), 1802, 2021 | 9 | 2021 |
| Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre M Saigí, M Oliva, L Aliste, M Calvo, G Hormigo, Ò Serra, A Boladeras, ... Plos one 12 (9), e0184737, 2017 | 8 | 2017 |
| MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer JJ Alburquerque-Bejar, P Navajas-Chocarro, M Saigi, A Ferrero-Andres, ... Cell Reports Medicine 4 (4), 2023 | 5 | 2023 |
| Identification of Actionable genetic targets in primary cardiac sarcomas C Salvador-Coloma, M Saigí, R Díaz-Beveridge, RM Penín, M Pané-Foix, ... OncoTargets and therapy, 9265-9275, 2019 | 5 | 2019 |
| Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer M Saigí, E Carcereny, T Morán, M Cucurull, M Domènech, A Hernandez, ... Cancer Treatment Reviews 109, 102430, 2022 | 4 | 2022 |
| Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. Cancer Discov. 2021; 11: 1952–1969. doi: 10.1158/2159-8290 NR Mahadevan, EH Knelson, JO Wolff, A Vajdi, M Saigí, M Campisi, ... CD-20-0913.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 4 | |
| 1658P Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED) A Plaja, T Moran, E Carcereny, A Bernat, AM Cardus, A Hernández, ... Annals of Oncology 32, S1168, 2021 | 2 | 2021 |
